At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 201 enrolled
Drug / intervention
Prasugrel +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Protocol H7T-MC-TABL(a) PRasugrel IN Comparison to Clopidogrel for Inhibition of PLatelet Activation and AggrEgation (PRINCIPLE) - TIMI 44
In Brief
A Phase 2 clinical trial evaluating Prasugrel, Clopidogrel, and 2 other interventions for Coronary Artery Disease. Completed, enrolled 201 participants across 16 sites in 4 countries.
Detailed Summary
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention (PCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesFrance, Germany, Israel, United States
CollaboratorsDaiichi Sankyo, The TIMI Study Group
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2006
Enrollment StartAug 2006
Primary CompletionJun 2007
TodayJul 2026
First PostedJul 28, 2006
Enrollment StartAug 1, 2006
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.9 years ago
Interventions
Prasugreldrug
Administered orally
Clopidogreldrug
Administered orally
Placebo for Prasugreldrug
Administered orally
Placebo for Clopidogreldrug
Administered orally